CDC Issues Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab

Published: 01/08/2024

  • Centers for Disease Control and Prevention
Relevant To:
  • Urgent Care,
  • Medical Office,
  • Critical Access Hospitals,
  • Hospitals,
  • Ambulatory Care,
  • Rural Health Clinics

On October 23, 2023, the Centers for Disease Control and Prevention (CDC) issued guidance for prioritization of nirsevimab given limited supply of the medication. Nirsevimab (Beyfortus, Sanofi and AstraZeneca) is a long-acting monoclonal antibody immunization recommended for preventing RSV-associated lower respiratory tract disease in young children.

Given the recent increase in nirsevimab supply and the manufacturers’ plan to release an additional 230,000 doses in January, CDC is advising he

Sign Up for Free Trial